Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care products giant Johnson & Johnson (JNJ -1.15%) has earned a respected four-star ranking.
With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.
J&J facts
|
Headquarters (founded) |
New Brunswick, N.J. (1886) |
|
Market Cap |
$265.1 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$70.0 billion |
|
Management |
Chairman/CEO Alex Gorsky |
|
Return on Equity (average, past 3 years) |
17.9% |
|
Cash/Debt |
$25.1 billion / $15.0 billion |
|
Dividend Yield |
2.8% |
|
Competitors |
Covidien |
Sources: S&P Capital IQ and Motley Fool CAPS.
Earlier this summer, CAPS member NHWeston102 succinctly summed up the J&J bull case for our community:
JnJ has taken its lumps of late, but it is still a global company with a huge spectrum of well-known brands from baby-powder to band-aids. They are not afraid to buy pioneering companies to catch a leg up on the competition, but JnJ still retains a strong innovative edge of its own. Look, for example, at INVOCANA, a diabetes drug that controls glucose levels through urine stream rather than insulin regulation. A classic buy-and-hold blue chip that still has serious class!!
